Clinical Trial
PNOC003: A pilot trial testing the clinical benefit of using molecular profiling to determine an individualized treatment plan in children and young adults with newly diagnosed DIPG
PNOC003 Study Publication
PNOC003 is now closed, and clinical trial results are now available as published in the Clinical Cancer Research in September 2022.
viewable here:
This study will use a new treatment approach based on each patient’s tumor gene expression and whole exome sequencing. The study will test the feasibility of a specialized tumor board assigning a treatment plan based on gene expression analysis, whole exome sequencing, and predictive modeling to establish a molecular-based-therapy approach at initial diagnosis. The treatment plan will take into consideration each patient’s tumor expression profile, gene mutations, and predictive modeling, as well as prior history and treatment(s), other medical conditions, and the age of the patient.
To determine OS12 of children with newly diagnosed DIPG that are being treated based on a specialized tumor board recommendation which is based on RNA based expression analysis, WES and predictive modeling for children and young adults with newly diagnosed DIPG.
This study is closed to accrual.
Funding is provided by The V Foundation.
PNOC003 Study Publication
PNOC003 is now closed, and clinical trial results are now available as published in the Clinical Cancer Research in September 2022.
viewable here:
This study will use a new treatment approach based on each patient’s tumor gene expression and whole exome sequencing. The study will test the feasibility of a specialized tumor board assigning a treatment plan based on gene expression analysis, whole exome sequencing, and predictive modeling to establish a molecular-based-therapy approach at initial diagnosis. The treatment plan will take into consideration each patient’s tumor expression profile, gene mutations, and predictive modeling, as well as prior history and treatment(s), other medical conditions, and the age of the patient.
To determine OS12 of children with newly diagnosed DIPG that are being treated based on a specialized tumor board recommendation which is based on RNA based expression analysis, WES and predictive modeling for children and young adults with newly diagnosed DIPG.
This study is closed to accrual.
Funding is provided by The V Foundation.
Sites Offering This Trial
How to Enroll
If you believe your child or patient is eligible for this trial, contact the closest participating site or email us for more information.